Navigation Links
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Date:3/10/2008

Company to host conference call Today, Monday, March 10, 2008 at 8:30am

NEW YORK, March 10 /PRNewswire-FirstCall/ -- On Friday, March 7, 2008, Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase the proportion of patients that achieve therapeutic success at 6 months as compared to placebo over background therapy of maximal doses of ACE-inhibitors or ARBs. Therapeutic success was defined as (i) conversion from microalbuminuria to normoalbuminuria, as measured by albumin/creatinine ratio (ACR), with at least a 25% reduction in ACR relative to baseline ACR, or (ii) a 50% reduction in ACR relative to baseline ACR. In addition, in reviewing the mean changes in ACR over time, Sulonex and placebo appeared to be similar.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, commented, "We are all very disappointed with the outcome of this Study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky and, accordingly, we have spent the last several years building what we believe to be a promising product portfolio in the event our lead drug failed. We plan to re-focus our primary efforts and resources on rapidly moving Zerenex forward for ESRD patients with hyperphosphatemia and Perifosine forward for cancer. Our goal is to have Perifosine in a pivotal program this year and be well into our Zerenex high- dose Phase 2 trial before the end of the year."

In order to participate in this morning's c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
3. Keryx Biopharmaceuticals Announces Additions to Management Team
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 The SNIS ... with $25,000 to fund a translational research project.  ... 2011, the gift was presented at the Society ... Meeting in Colorado Springs, CO. ... neurointerventional approaches to neurovascular conditions, SNIS formed the ...
(Date:7/31/2014)... PORTOLA VALLEY, Calif. , July 31, 2014 /PRNewswire/ ... San Francisco Bay Area , has ... the University of Oxford,s commercialisation company. The potent anti-inflammatory ... David Greaves at the University of Oxford,s Sir ... The company, which has raised over $1.5 million ...
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 North ... New York City, partnered with GI Energy, one of the ... complete a $13 million upgrade of its 43-year-old CHP system. ... 1971 and in an effort to extend the life of ... six generators and associated electrical and heat recovery equipment, while ...
(Date:7/31/2014)... 31, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... the study of the genetic material or genomes of ... basis for the discovery and development of diagnostic and ... health conditions. Genomics is supported by three major product ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Feb. 16, 2012  BioDelivery Sciences International, Inc. (Nasdaq: ... Office (USPTO) has issued a Notice of Allowance of ... will extend the exclusivity of the BioErodible MucoAdhesive (BEMA) ... from 2020 to 2027.  A Notice ...
... ANN ARBOR, Mich., Feb. 16, 2012  Adeona Pharmaceuticals, Inc. ... synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious ... meeting of stockholders to change its corporate name to ... shares will start trading under its new name and ...
... University of British Columbia professor has developed a new class ... sudden loss of consciousness in rats, and which are ... as "petit mal seizures," are a symptom of epilepsy, most ... awake but dazed. The seizures, arising from a flurry of ...
Cached Biology Technology:BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 2BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 3BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 4BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals 5New drugs show promise for preventing 'absence seizures' in children: UBC research 2
(Date:7/31/2014)... many of the roughly 156,000 gas stations across ... in parts of underground gas storage tankscorrosion that ... groundwater, a source of drinking water. In recent ... many rapidly corroding gas storage tank components such ... with use of gasoline-ethanol blends and the presence ...
(Date:7/31/2014)... Neb., July 31, 2014 -- Do people make a ... mothers raise them that way? Is it a matter ... Nebraska-Lincoln and a colleague from Rice University say that ... some people lean left while others lean right. , ... and deep-seated psychology are at the core of political ...
(Date:7/31/2014)... as the Rim Fire was in full fury, raging ... it entered the backcountry of Yosemite National Park in ... the park, the battle began to turn, enacting a ... can combine to fuel large, severe fires. , "When ... lands where fire had been used as a management ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2Scientists find growing consensus: Political attitudes derive from body and mind 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... researchers at Scottsdale Healthcare and TGen today announced the ... patients battling cancer. The Phase I clinical ... of the American Association for Cancer Research by Daniel ... (BCC) and pancreatic cancer. The Arizona trials were conducted ...
... This release is available in French . ... Generation Investment Management, the private bankers Lombard Odier Darier ... new chair at EPFL dedicated to sustainable development. The ... education between fundamental and social sciences in the environmental ...
... April 2008 -- European breast cancer specialists have taken ... breast cancer by bringing together world leaders in breast ... meeting, IMPAKT (IMProving cAre and Knowledge in Translational ... held 7-9 May 2009 in Brussels, Belgium, is designed ...
Cached Biology News:2 new therapies show promise for cancer patients 22 new therapies show promise for cancer patients 3EPFL Research Day 2008, in the presence of Al Gore 2EPFL Research Day 2008, in the presence of Al Gore 3Improving care and knowledge in translational research to fight breast cancer 2
... 45° Fixed Angle Rotor for ... CL2, Centra CL3CL3R, and Centra-MP4/MP4R. ... of sputum samples and other ... Provides individual aerosol containment. Complete ...
... The MBS Satellite Thermal Cycler ... flexible solution for medium to ... MBS combines the latest in ... software and PC control, resulting ...
... Block MBS Start up kit. Includes configured ... choice of 2 MultiBlock satellite thermal ... blocks. User friendly software. Store/track ... height heated lid. Outstanding uniformity. ...
... Magnetic Stirrers operate without any moving parts ... making VARIOMAG Magnetic Stirrers 100% wear-free and ... can be hermetically sealed, making it inaccessible ... why VARIOMAG Magnetic Stirrers are particularly suitable ...
Biology Products: